Scientists have identified a molecule that appears to restore the immune system's ability to fight Alzheimer's disease by reprogramming the brain cells responsible for clearing toxic debris. The compound, called OLE, reactivates microglia, specialized immune cells that normally protect the brain but become progressively impaired in Alzheimer's patients.
A multinational research team led by José Vicente Sánchez Mut at Spain's Institute for Neurosciences and Johannes Gräff at Switzerland's École Polytechnique Fédérale de Lausanne published their findings in Cell Death and Disease. The work centers on a fundamental problem in Alzheimer's disease: as microglia weaken over time, they fail to remove beta-amyloid plaques that accumulate in the brain and damage neurons.
OLE, derived from the PM20D1 gene, reverses this decline by pushing microglia back into a protective state. Once activated, these immune cells migrate toward beta-amyloid plaques, surround them, and create a barrier that prevents the toxic deposits from contacting nearby brain cells. In laboratory tests, this process reduced the size and harmful effects of the plaques.
The researchers tested OLE on multiple organisms. In genetically modified worms engineered to produce beta-amyloid, treatment reduced protein buildup and improved movement. In mouse models of Alzheimer's disease, animals that received OLE for three months performed better on memory tests and showed fewer plaques than untreated controls.
Single-cell analysis revealed that microglia responded most dramatically to the treatment. After exposure to OLE, these cells activated pathways needed to clear amyloid and regained mobility to track down and contain plaques. In cell cultures, similar results emerged: microglia treated with OLE moved more effectively toward beta-amyloid deposits, and neurons exposed to Alzheimer's-like conditions survived better when OLE was present.
Sánchez Mut emphasized the significance of the discovery. "One of the most significant findings is that we have identified a molecule capable of restoring microglia's protective function," he said. "In Alzheimer's disease, these cells become progressively impaired. Our results suggest that this process can be reversed, pointing to new therapeutic and research avenues to counteract the disease."
The research is protected by two European patents, including one held by Spain's National Research Council. This intellectual property position strengthens the pathway toward developing treatments based on the discovery for human patients.
Author Jessica Williams: "If OLE translates to humans the way it works in these models, we could be looking at a genuinely different approach to Alzheimer's, not just slowing decline but actually restoring what the disease has broken."
Comments